Department of Neonatal Intensive Care and Neonatal Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland.
Paediatric Nephrology Ward with Dialysis Division for Children, Public Clinical Hospital No. 1 in Zabrze, Poland.
Endokrynol Pol. 2020;71(4):334-342. doi: 10.5603/EP.a2020.0044.
Renalase is a recently identified flavoprotein oxidase, secreted mainly by the kidneys, which takes part in the degradation of catecholamines. The catecholamine inactivating effect results in the modulation of the sympathetic system tension and, consequently, in a decrease of blood pressure, myocardial contractility, heart rate, and vascular tone. Besides its enzymatic capacity, renalase shows cytoprotective properties by activating mitogen-activated protein kinase (MAPK) pathway. Several single nucleotide polymorphisms (SNPs) of the renalase gene have been identified, of which the most widely studied in relation to the development of selected diseases are rs2296545, rs10887800, and rs2576178. Numerous publications prove the contribution of renalase to the occurrence of cardiovascular diseases, kidney diseases, ischaemic stroke, diabetes type 1 and 2, as well as female infertility and schizophrenia. Further extended research into the various mechanisms of renalase activity may result in the use of this oxidase or its analogues as a therapeutic and/or diagnostic tool.
肾酶是一种新近发现的黄素蛋白氧化酶,主要由肾脏分泌,参与儿茶酚胺的降解。儿茶酚胺失活作用导致交感神经系统张力的调节,进而导致血压、心肌收缩力、心率和血管张力降低。除了其酶活性外,肾酶还通过激活丝裂原活化蛋白激酶(MAPK)通路显示出细胞保护特性。已经鉴定出肾酶基因的多个单核苷酸多态性(SNP),其中与某些疾病发展相关的最广泛研究的是 rs2296545、rs10887800 和 rs2576178。大量出版物证明了肾酶在心血管疾病、肾脏疾病、缺血性中风、1 型和 2 型糖尿病以及女性不孕和精神分裂症中的作用。对肾酶活性的各种机制的进一步扩展研究可能导致使用这种氧化酶或其类似物作为治疗和/或诊断工具。